[
  {
    "ts": null,
    "headline": "PTC Therapeutics (PTCT): Assessing Valuation After New Huntington’s Data Shifts Competitive Landscape and Investor Sentiment",
    "summary": "If you’re holding or eyeing shares in PTC Therapeutics (PTCT), recent news probably has your full attention. uniQure’s Phase 1/2 gene therapy results for Huntington’s disease made waves by showing a 75% reduction in disease progression. This has sparked immediate questions about how PTC’s votoplam program might compare to such competition. With the spotlight shifting away from PTC’s own development and insider selling coming to light, investors are analyzing what these events mean for future...",
    "url": "https://finnhub.io/api/news?id=512c04e8edb90d7d3c32abdfb1289fd2e1dc977f57c694964e3166fca521c17f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1759145482,
      "headline": "PTC Therapeutics (PTCT): Assessing Valuation After New Huntington’s Data Shifts Competitive Landscape and Investor Sentiment",
      "id": 136914186,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PTC",
      "source": "Yahoo",
      "summary": "If you’re holding or eyeing shares in PTC Therapeutics (PTCT), recent news probably has your full attention. uniQure’s Phase 1/2 gene therapy results for Huntington’s disease made waves by showing a 75% reduction in disease progression. This has sparked immediate questions about how PTC’s votoplam program might compare to such competition. With the spotlight shifting away from PTC’s own development and insider selling coming to light, investors are analyzing what these events mean for future...",
      "url": "https://finnhub.io/api/news?id=512c04e8edb90d7d3c32abdfb1289fd2e1dc977f57c694964e3166fca521c17f"
    }
  }
]